Sorrento Therapeutics, Inc.
4955 Directors Pl.
San Diego
California
92121
United States
Website: http://sorrentotherapeutics.com/
About Sorrento Therapeutics, Inc.
163 articles with Sorrento Therapeutics, Inc.
-
1st Patient Treated for Osteoarthritis Knee Pain in Sorrento Resiniferatoxin Phase 1B Trial Meets Both Safety and Efficacy Expectations
8/13/2018
Sorrento Therapeutics, Inc. announced that the first enrolled patient in the phase 1b study of its non-opioid, afferent nerve ablating drug candidate (resiniferatoxin or “RTX”) for the treatment of pain from osteoarthritis in the knee (intra-articular route of administration) received treatment on July 31, 2018.
-
The Loncar Cancer Immunotherapy Index has reduced the number of immunotherapy-focused companies from 30 to 25 and also swapped out a number of stocks as part of an effort to strengthen the index’s liquidity profile and ensure the holdings hold equal weight.
-
If a brand name drug loses patent protection, that often marks the date when companies can begin marketing generic versions of the drug. However, this has grown more complicated with the approvals of biosimilars.
-
Sorrento Therapeutics, Inc. nabbed regulatory approval for ZTlido, a non-opioid pain treatment in the form of a super-sticky patch.
-
3 Biotech Stocks That Soared Recently
2/19/2018
Three biotech stocks gained over 25 percent last week. -
Sorrento’s And Yuhan’s Joint Venture, Immuneoncia, Receives Approval to Begin Clinical Trial of Anti-PD-L1 Monoclonal Antibody in South Korea
2/5/2018
Yuhan had initially contributed more than $10M to the formation of ImmuneOncia and towards the development of IMC-001.
-
Sorrento Therapeutics Chairman/CEO Letter to Stockholders
2/5/2018
In the letter, the CEO shares some of the company's 2017 achievements as well as his thoughts for both our near and long-term future.
-
China Oncology Focus Limited Receives Approval by Chinese Authorities to Begin Clinical Trials in Three Separate Cancer Indications Using Sorrento’s Anti-PD-L1 Monoclonal Antibody
1/29/2018
The trials will be anticipated to use a 3+3 design with 5mg/kg, 10mg/kg and 15mg/kg dosing regimens. O
-
Sorrento Therapeutics CAR-T Manufacturing Capacity Expanded With Opening of East Coast GMP Site in Addition to Primary West Coast Facility
1/24/2018
Sorrento estimates that the combination of its East and West Coast manufacturing capacity will allow the company to process CAR-T treatments for over 300 patients a year without the use of a third-party contract manufacturer.
-
Sorrento Therapeutics to Present Potential “Game-Changer” Non-Viral CAR-T Technology for Autologous and Allogeneic (off-the-shelf) CAR-T Therapies
1/2/2018
This novel Sorrento CAR-T technology has already been utilized preclinically to generate CD38 CAR-T and CD19 CAR-T cells.
-
Scilex Pharma, Sorrento's Subsidiary, Files MAA in the European Union for ZTlido
11/14/2017
Sorrento announced today that Scilex Pharma filed the European MAA for its lead product candidate, ZTlido through a hybrid regulatory pathway with the MHRA in the UK.
-
Sorrento Appoints Mr. Dorman Followwill And Mr. Dave Lemus To The Board Of Directors
10/2/2017
-
FDA Acknowledges Receipt Of Sorrento, NDA For ZTlido; PDUFA Date Set For February 28, 2018
9/12/2017
-
Sorrento Submits NDA For ZTlido Next-Generation Lidocaine Patch
8/29/2017
-
Sorrento Announced FDA Authorization Of IND To Commence Clinical Trial Of RTX In Intractable Cancer Pain
6/29/2017
-
Sorrento Announces Dismissal Of Lawsuits
6/15/2017
-
Sorrento' Pain Subsidiary, Scilex, Announces Positive Data From Head To Head Adhesion Study With Its Lead Product, ZTlido
6/14/2017
-
Human Longevity Co-Founder To Helm Newly Launched Sorrento Spinoff Celularity
6/13/2017
-
Sorrento Announces The Completion Of GMP Manufacturing Plant In Suzhou, China To Support Its Growing Antibody-Drug Conjugate (ADC) Pipeline And Service Business
5/4/2017
-
Sorrento Announces Closing Of Its Acquisition Of Virttu Biologics
4/28/2017